Anti-Human IL-13 SAFIRE Purified

Grouped product items
Size Price Qty

Additional PVM13-1 Formats

Cat.No. Format Starting From
83511-25 SAFIRE Purified $ 110.00
Catalog Number : 83511-25


The PVM13-1 monoclonal antibody bings to human IL-13. IL-13 is an immunoregulatory cytokine produced primarily by activated Th2 cells, and also by mast cells and NK cells. Targeted deletion of IL-13 in mice resulted in impaired Th2 cell development and indicated an important role for IL-13 in the expulsion of gastrointestinal parasites. IL-13 exerts anti-inflammatory effects on monocytes and macrophages and it inhibits the expression of inflammatory cytokines such as IL-1β, TNF-α, IL-6 and IL-8. IL-13 has also been shown to enhance B cell proliferation and to induce isotype switching, resulting in increased production of IgE. Blocking of IL-13 activity inhibits the pathophysiology of asthma. The PVM13-1 antibody is reported to be a neutralizing antibody.

Additional Information

SAFIRE Purified
FA, Neutralization
Mouse IgG1
Research Interest: Adaptive Immunity
Cell Type: T Cells
Application: FA, Neutralization
Clone: PVM13-1
The product should be stored undiluted at 4°C. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography.
Phosphate-buffered aqueous solution, ph7.2.

Hansmann, L., Schmidl, C., Kett, J., Steger, L., Andreesen, R., Hoffmann, P., ... & Edinger, M. (2012). Dominant Th2 differentiation of human regulatory T cells upon loss of FOXP3 expression. The Journal of Immunology188(3), 1275-1282.

Fuschiotti, P., Medsger, T. A., & Morel, P. A. (2009). Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin‐13 associated with increased skin fibrosis. Arthritis & Rheumatism60(4), 1119-1128.

Yamashita, Y., Hoshino, Y., Oka, M., Matsumoto, S., Ariga, H., Nagai, H., ... & Tsunetsugu-Yokota, Y. (2013). Multicolor flow cytometric analyses of CD4+ T cell responses to Mycobacterium tuberculosis-related latent antigens.Japanese journal of infectious diseases66(3), 207-215.

© BioGems International, Inc. All rights reserved.